Professor Nicholas Harvey, IOF President, lauded Dr. Chevalley for his unwavering commitment to the Foundation’s initiatives. Harvey emphasized Chevalley’s leadership as Vice-Chair of the governance board of the Capture the Fracture® programme, an initiative dedicated to the reduction of fracture risks worldwide through systematic post-fracture care coordination. Dr. Chevalley’s extensive involvement in the IOF Committee of Scientific Advisors and various scientific programs has been instrumental in shaping contemporary osteoporosis research and preventive strategies, highlighting his influential position in the international bone health community.

Dr. Chevalley’s academic journey reflects a profound dedication to osteology and geriatric medicine. Earning his medical degree from the University of Lausanne, he pursued doctoral studies at the University of Geneva, focusing his research on calcium supplementation and its impact on bone mineral density and fracture incidence among elderly populations. This work illuminated critical aspects of nutritional interventions in osteoporosis management, providing evidence-based guidance for clinical recommendations targeting older adults at high risk of fractures.

Upon completing postdoctoral research at Loma Linda University in California, Dr. Chevalley joined Geneva University Hospitals, where he assumed key roles including Head of the Geriatrics Liaison Unit and Consulting Physician in Bone Diseases. His multidisciplinary expertise encompasses the intersection of geriatrics and metabolic bone diseases, enabling him to contribute significantly to patient-centered approaches in fracture prevention and osteoporosis care. His clinical insights have informed both regional and international protocols for managing bone fragility.

As an internationally recognized authority on osteoporosis, Dr. Chevalley contributes to multiple high-profile advisory boards, including the IOF Committee of Scientific Advisors and the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO). His vice-chair position within the Capture the Fracture® programme’s governance structure underscores his leadership in promoting fracture liaison services (FLS), a systematic approach aimed at identifying and managing patients after fragility fractures to prevent subsequent fractures.

In addition to his organizational roles, Dr. Chevalley is a vital contributor to scientific literature, serving as Associate Editor for prestigious journals such as Osteoporosis International and Archives of Osteoporosis. His publication record, with over 8,000 citations, spans a broad spectrum of topics including the efficacy of fracture liaison services, bone health across the lifespan, and the complex relationships between nutrition, growth, and aging in skeletal homeostasis. His research continues to influence both clinical practice and health policy aimed at reducing the burden of musculoskeletal diseases.

Dr. Chevalley has been particularly active in promoting the development and implementation of fracture liaison services in Switzerland, collaborating with the Swiss Association Against Osteoporosis (ASCO). These services represent a paradigm shift in secondary fracture prevention, focusing on coordinated care pathways that integrate orthopedic care with osteoporosis assessment and treatment. His advocacy helps bridge gaps between acute fracture care and long-term bone health management, aiming to reduce recurrent fracture rates and associated morbidity.

The recognition of Dr. Chevalley’s contributions at WCO-IOF-ESCEO 2026, the world’s largest annual congress dedicated to bone, muscle, and joint diseases, reaffirms the critical importance of translational science in musculoskeletal health. The congress serves as an essential platform where researchers and clinicians converge to disseminate cutting-edge clinical research and explore therapeutic advancements in conditions such as osteoporosis, osteoarthritis, sarcopenia, and rare skeletal disorders.

Through his work, Dr. Chevalley exemplifies the integration of clinical expertise, research excellence, and organizational leadership necessary to tackle the complex challenges posed by musculoskeletal diseases. His efforts resonate beyond academia, influencing healthcare delivery systems worldwide and encouraging multidisciplinary collaboration to improve patient outcomes through evidence-based interventions.

The award reflects not only past achievements but also Dr. Chevalley’s ongoing commitment to innovation in fracture prevention and skeletal health. His involvement with global initiatives, coupled with his focus on geriatric populations and metabolic bone disease, positions him at the forefront of developing strategies that address aging-related bone loss and fracture risk reduction.

The IOF President’s Award bestowed upon Dr. Thierry Chevalley acknowledges a career dedicated to enhancing the understanding and clinical management of bone diseases, particularly osteoporosis, which remains a significant public health challenge globally. His intricate understanding of the biological mechanisms underpinning bone fragility and his advocacy for integrated care services underpin efforts to reduce the incidence and impact of fractures worldwide.

As the global population ages, the importance of experts like Dr. Chevalley in guiding policy and clinical practice cannot be overstated. His scientific contributions and leadership continue to shape the future of musculoskeletal health, aiming toward a world where fractures and their debilitating consequences are significantly diminished through innovation, education, and coordinated healthcare delivery.

Subject of Research: Osteoporosis, fracture prevention, fracture liaison services, bone health in geriatrics, effects of calcium supplementation on bone density

Article Title: International Osteoporosis Foundation Honors Dr. Thierry Chevalley with IOF President’s Award for Advancing Global Bone Health

News Publication Date: April 16, 2026

Web References:

• https://www.wco-iof-esceo.org/
• https://www.osteoporosis.foundation/

Keywords: Osteoporosis, fracture prevention, geriatrics, bone health, fracture liaison services, calcium supplementation, metabolic bone disorders, musculoskeletal diseases, aging, IOF President’s Award, Capture the Fracture®, clinical research, osteoporosis management

The study published in the Archives of Osteoporosis emphasizes the importance of treatment frequency in managing osteoporosis effectively. Traditionally, teriparatide, a synthetic form of parathyroid hormone, has been administered daily. In their investigation, Tominaga et al. explored whether reducing the dosing frequency while maintaining therapeutic outcomes would be feasible. By adjusting the treatment regimen, clinicians may potentially enhance patient adherence, which is crucial for long-term management of osteoporotic conditions.

The research focused on a cohort of postmenopausal women diagnosed with osteoporosis. This demographic is most at risk for osteoporosis-related fractures, making it imperative to explore treatment methods that can enhance their quality of life. Preliminary findings indicated that those receiving a twice-weekly regimen exhibited improvements not just in bone density but also in overall fracture risk reduction. This is particularly encouraging, as non-compliance to daily medication regimens has frequently been cited as a significant barrier to effective osteoporosis treatment.

Furthermore, the study highlighted both the biochemical and clinical markers of bone health that were positively influenced by the reduced frequency of teriparatide administration. Notable is the increase in bone mineral density, a key indicator of bone health. The participants who adhered to this new dosing schedule demonstrated results comparable to those who had been on the conventional daily therapy. This breakthrough suggests that patients may experience similar benefits with fewer injections, ultimately enhancing their treatment experience.

Safety is often a paramount consideration in pharmacological treatment plans, especially in elderly populations who may have comorbidities and be on multiple medications. The research team meticulously monitored for any adverse effects associated with the twice-weekly administration of teriparatide. Initial results indicate a similar safety profile to that of daily administration, which would be critical in broadening the acceptance of this treatment protocol. Continued monitoring, however, is essential to understand the long-term impacts fully.

The implications of this study could extend beyond just the treatment of osteoporosis. With the ongoing evolution in the field of healthcare towards personalized medicine, findings like these pave the way for an adaptive approach to treatment. As evidence mounts regarding improved patient outcomes with modified dosing frequencies, guidelines might evolve to incorporate these findings, encouraging clinicians to tailor treatments based on individual patient needs and lifestyles.

Moreover, the economic aspect of osteoporosis treatments cannot be overlooked. The frequency of injections and overall healthcare costs associated with managing osteoporosis can place a significant burden on both healthcare systems and patients. By reducing the injection frequency, the financial implications of osteoporosis management could be substantially lowered, making treatment more accessible.

The researchers did not limit their analyses to solely clinical and biochemical data. They also incorporated patient-reported outcomes to capture the overall impact on quality of life. Perspectives from the participants shed light on the psychological and emotional facets of living with osteoporosis and undergoing treatment. This holistic view underscores the necessity of involving patients in their treatment plans and acknowledging their preferences and experiences, which can greatly influence adherence and outcomes.

Public response to the findings is likely to garner considerable interest, as patients seek more manageable solutions to their health challenges. This research may empower individuals with osteoporosis to advocate for their treatment preferences, leading to a more engaged patient population. As studies like this gain traction, there is potential for increased awareness of osteoporosis management techniques, emphasizing the importance of research-driven treatment.

Concerning practical implementation, healthcare providers may need to engage in further education regarding this novel regimen. As clinicians remain vigilant about emerging research, integrating new findings into practice will be essential. Medical professionals may need to recalibrate their approach to discussing treatment options with patients, highlighting the benefits of a more flexible administration schedule.

In summary, Tominaga et al.’s study on the clinical outcomes of twice-weekly teriparatide administration is a significant contribution to osteoporosis research. It opens the door to reimagining treatment paradigms and may ultimately shift existing protocols toward more patient-centered care models. As the healthcare landscape evolves, such breakthroughs remind us of the critical importance of evidence-based practice in fostering advancements in patient care.

Looking ahead, further investigations will be essential to validate these findings across diverse populations and settings. Long-term clinical trials will be required to assess the sustainability and efficacy of this treatment approach. The implications of this research, if affirmed by future studies, could indeed pave the way for changes in osteoporosis treatment guidelines and offer renewed hope to millions affected by this debilitating disease.

Ultimately, advances in osteoporosis treatment not only hold promise for individual patients but also herald a broader revolution in chronic disease management. As exciting new data emerges, the commitment to facilitating improved outcomes for patients will remain at the forefront of the healthcare agenda, ensuring that science continues to serve humanity’s needs.

Subject of Research: Osteoporosis treatment with teriparatide acetate

Article Title: Clinical outcomes of twice-weekly teriparatide acetate administration in osteoporosis

Article References: Tominaga, A., Maruki, H., Wada, K. et al. Clinical outcomes of twice-weekly teriparatide acetate administration in osteoporosis. Arch Osteoporos 20, 144 (2025). https://doi.org/10.1007/s11657-025-01622-4

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s11657-025-01622-4

Keywords: Osteoporosis, teriparatide acetate, twice-weekly administration, bone density, treatment compliance, health outcomes.